Trials / Completed
CompletedNCT00658567
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin tartrate (ACP-103) | 10 mg, tablet, once daily by mouth, for six weeks |
| DRUG | Pimavanserin tartrate (ACP-103) | 20 mg, tablet, once daily by mouth, for six weeks |
| DRUG | Pimavanserin tartrate (ACP-103) | Placebo, tablet, once daily by mouth, for six weeks |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-04-15
- Last updated
- 2017-05-19
- Results posted
- 2014-09-09
Locations
50 sites across 9 countries: United States, Austria, Belgium, Italy, Poland, Portugal, Serbia, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00658567. Inclusion in this directory is not an endorsement.